Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock performance was -3.38% in last session and finished the day at $40.00. Traded volume was 1.89million shares in the last session and the average volume of the stock remained 167.87K shares. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) insider ownership is 2.90%.

Prosensa Holding N.V. (NASDAQ:RNA) filed a $150 million mixed securities shelf. The company also filed to sell up to 18,908,019 Ordinary Shares on behalf of Selling Shareholders. Prosensa Holding NV (NASDAQ:RNA) dropped -7.29 percent to $9.66 Wednesday on volume of 352,315.00million shares. The intra-day range of the stock was $9.56 to $10.52. Prosensa Holding NV (NASDAQ:RNA) has a market capitalization of $347.52million.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Insider Scott Biller unloaded 4,500 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $46.52, for a total value of $209,340.00. Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s stock on July 09, 2014 reported a decrease of -0.45% to the closing price of $39.40. Its fifty two weeks range is $15.77 -$50.37. The total market capitalization recorded $1.31billion. The overall volume in the last trading session was 410,100.00million shares. In its share capital, AGIO has 33.96million outstanding shares.

Seattle Genetics Inc. (NASDAQ:SGEN) announced today that it will report its second quarter 2014 financial results on Thursday July 31 2014 after the close of financial markets. Following the announcement company management will host a conference call and webcast discussion of the results and provide a general corporate update. On Wednesday, shares of Seattle Genetics, Inc. (NASDAQ:SGEN) advanced 0.79% to close the day at $35.74. Company return on investment (ROI) is -27.30% and its monthly performance is recorded as -7.46%. Seattle Genetics, Inc. (NASDAQ:SGEN) quarterly revenue growth is -13.02%.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that it will be added to the Russell 3000(R) and Russell 2000(R) Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 27, 2014, according to a preliminary list of additions posted on June 13, 2014 on Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock performance was 0.38% in last session and finished the day at $2.67. Traded volume was 1.00million shares in the last session and the average volume of the stock remained 2.11million shares. The beta of the stock remained 2.57. Idera Pharmaceuticals Inc (NASDAQ:IDRA) insider ownership is 0.50%.